Research Progress on the Application of Liquid Biopsy in the Diagnosis
and Treatment of Small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2022.101.22
- Author:
Xiaomin ZHANG
1
;
Mengyuan XU
1
;
Xichuan LI
1
;
Yanjun SU
2
Author Information
1. Tianjin Key Laboratory of Animal and Plant Resistance, College of Life Sciences, Tianjin Normal University, Tianjin 300387, China.
2. Key Laboratory of Cancer Prevention and Therapy, Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
- Publication Type:Journal Article
- Keywords:
Circulating tumour DNA;
Circulating tumour cells;
Exosomes;
Liquid biopsy;
Lung neoplasms
- MeSH:
Biomarkers, Tumor;
Circulating Tumor DNA;
Humans;
Liquid Biopsy;
Lung Neoplasms/therapy*;
Neoplastic Cells, Circulating/metabolism*;
Small Cell Lung Carcinoma/therapy*
- From:
Chinese Journal of Lung Cancer
2022;25(8):609-614
- CountryChina
- Language:Chinese
-
Abstract:
Small cell lung cancer (SCLC) is a malignant tumor with strong invasiveness and high mortality. It has the characteristics of easy metastasis, fast growth, high degree of malignancy and strong invasiveness. The prognosis of patients is generally poor. The current clinical diagnosis of SCLC is mainly based on tissue biopsy, which is invasive, long cycle time and high cost. In recent years, liquid biopsy has been gradually applied because of its non-invasive, comprehensive and real-time characteristics that traditional tissue biopsy does not have. The main detection objects of liquid biopsy include circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) and exosomes in peripheral blood. The application of liquid biopsy in the clinical treatment of SCLC will help clinicians to improve the detailed diagnosis of SCLC patients, as well as the timely control and response to the treatment response of patients.
.
